Abstract
The socio-economic burden of renal disease is enormous due to the unavailability of effective treatment to cure it. High risk patients have only two costly options in chronic renal disease, dialysis and renal replacement therapy (RRT). RRT has limitations of the organ donor, and ethical concerns are also associated with it. The Wnt/beta-catenin pathway is highly conserved and active during embryogenesis in early life but suppressed in adults. Animal studies suggested that knockdown of Wnt protein led to abnormal kidney development at birth. In the adult kidney, Wnt/beta-- catenin pathway activation led to tissue repair after acute injury, but sustained activation is harmful and involved in renal fibrosis. Recently, Wnt/beta-catenin signaling cascade has emerged as a potential pathway involved in adult renal diseases and is considered an attractive therapeutic target for developing effective therapeutic intervention. Precise information about the involvement of specific types of Wnt/beta-catenin pathway components in adult renal disease using cutting-edge molecular techniques will help develop novel therapies for renal diseases. Future studies will determine Wnt/beta-catenin signaling proteins' effectiveness and safety as a treatment option for renal disorders.
Keywords: Renal disease, Wnt/beta-catenin, signaling, therapeutic target, Wnt protein secretion, porcupine enzyme.
Current Drug Targets
Title:Canonical Wnt/Beta-Catenin Signaling Network as Emerging Signaling Cascade for Therapeutic Intervention in Chronic Renal Disease
Volume: 22 Issue: 16
Author(s): Hitesh Soni*
Affiliation:
- Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163,United States
Keywords: Renal disease, Wnt/beta-catenin, signaling, therapeutic target, Wnt protein secretion, porcupine enzyme.
Abstract: The socio-economic burden of renal disease is enormous due to the unavailability of effective treatment to cure it. High risk patients have only two costly options in chronic renal disease, dialysis and renal replacement therapy (RRT). RRT has limitations of the organ donor, and ethical concerns are also associated with it. The Wnt/beta-catenin pathway is highly conserved and active during embryogenesis in early life but suppressed in adults. Animal studies suggested that knockdown of Wnt protein led to abnormal kidney development at birth. In the adult kidney, Wnt/beta-- catenin pathway activation led to tissue repair after acute injury, but sustained activation is harmful and involved in renal fibrosis. Recently, Wnt/beta-catenin signaling cascade has emerged as a potential pathway involved in adult renal diseases and is considered an attractive therapeutic target for developing effective therapeutic intervention. Precise information about the involvement of specific types of Wnt/beta-catenin pathway components in adult renal disease using cutting-edge molecular techniques will help develop novel therapies for renal diseases. Future studies will determine Wnt/beta-catenin signaling proteins' effectiveness and safety as a treatment option for renal disorders.
Export Options
About this article
Cite this article as:
Soni Hitesh *, Canonical Wnt/Beta-Catenin Signaling Network as Emerging Signaling Cascade for Therapeutic Intervention in Chronic Renal Disease, Current Drug Targets 2021; 22 (16) . https://dx.doi.org/10.2174/1389450122666210216092218
DOI https://dx.doi.org/10.2174/1389450122666210216092218 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Conantokins: Peptide Antagonists of NMDA Receptors
Current Medicinal Chemistry New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry The p38α Kinase Plays a Central Role In Inflammation
Current Topics in Medicinal Chemistry Pharmacokinetic Analysis of Tetramethylpyrazine Bis-Nitrone TN-2 in Rats and its Protein Binding In Vitro
Letters in Drug Design & Discovery Notoginsenoside R1 Promotes the Growth of Neonatal Rat Cortical Neurons via the Wnt/β-catenin Signaling Pathway
CNS & Neurological Disorders - Drug Targets Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging The Importance of Lost Minerals in Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry New Anti-Anginal Drugs: Ranolazine
Cardiovascular & Hematological Agents in Medicinal Chemistry Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design The Role of IGF-1 Receptor and Insulin Receptor Signaling for the Pathogenesis of Alzheimers Disease: From Model Organisms to Human Disease
Current Alzheimer Research Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology Tetramethylpyrazine Facilitates Functional Recovery after Spinal Cord Injury by Inhibiting MMP2, MMP9, and Vascular Endothelial Cell Apoptosis
Current Neurovascular Research Non-Viral Gene Delivery Methods
Current Pharmaceutical Biotechnology Modulation of Neutrophil Development and Homeostasis
Current Molecular Medicine Endothelial Progenitor Cells at the Interface of Chronic Kidney Disease: From Biology to Therapeutic Advancement
Current Medicinal Chemistry Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Inhibition of Inflammation by a p38 MAP Kinase Targeted Cell Permeable Peptide
Medicinal Chemistry Can Life Before Birth Affect Health Ever After?
Current Women`s Health Reviews Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Current Pharmaceutical Design